Vocado HCT

Quick links

Choose a section

Quick links to important sections

Advertisements

Vocado HCT

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Vocado HCT

What Type of Medicine is Vocado HCT?

Vocado HCT is a synthetic, prescription-only medication classified as a triple-combination antihypertensive agent, specifically designed for the management of high blood pressure, or hypertension. This medicine is a fixed-dose combination (FDC) product, meaning it unites three distinct active drugs into a single oral tablet. Vocado HCT is utilized when blood pressure control has not been adequately achieved using therapy with only two agents. The FDC format is designed to support patient adherence to complex antihypertensive therapy, as taking one tablet is simpler than taking three separate medications.


Composition: A Three-in-One Antihypertensive Strategy

The composition of Vocado HCT includes three core active ingredients: Amlodipine, Olmesartan Medoxomil, and Hydrochlorothiazide (HCT). These three compounds belong to three separate and complementary pharmacological classes. Amlodipine is a Calcium Channel Blocker (CCB), Olmesartan Medoxomil is an Angiotensin II Receptor Blocker (ARB), and Hydrochlorothiazide is a Thiazide Diuretic. The grouping of these three agents into one medication is a distinctive feature, differentiating it from dual-combination tablets that omit the diuretic component. This three-class combination is a strategy for intensifying treatment in patients whose blood pressure remains uncontrolled.


What is the General Purpose of Vocado HCT?

The general purpose of Vocado HCT is to achieve blood pressure reduction by simultaneously engaging three primary physiological pathways. The three active components work to lower arterial pressure. The CCB and ARB components contribute to vascular relaxation and help prevent hormonal vessel constriction, while the diuretic component facilitates fluid regulation by promoting the excretion of salt and water. This combined, multi-pathway approach reduces the force exerted on arterial walls, which is the primary goal of using this multi-component drug for chronic essential hypertension.

Advertisements

What side effects are possible with Vocado HCT?

Possible Side Effects and Safety Information

The safety profile of Vocado HCT (Amlodipine/Olmesartan Medoxomil/Hydrochlorothiazide) is formally structured by government regulatory bodies, classifying adverse reactions by frequency and affected physiological system. The most frequently documented side effects are categorized as Common and typically involve Dizziness, Peripheral Edema (swelling), Headache, and Fatigue.


Adverse reactions are grouped into System-Organ Classes (SOCs), including Vascular disorders (e.g., hypotension), Nervous system disorders, and Metabolism and nutrition disorders (e.g., electrolyte imbalances like hypokalemia, linked to the diuretic component).


Serious Adverse Reactions and Safety Constraints

The official labeling notes specific serious safety concerns and constraints on use. Angioedema (swelling of the face, lips, or throat) is a documented serious reaction. Due to the Olmesartan component, the medicine is formally Contraindicated in Pregnancy during the second and third trimesters because of the risk of Fetal Toxicity.

Use is also contraindicated in patients with Anuria (lack of urine production), known Hypersensitivity to any component, or to other sulfonamide-derived drugs (due to Hydrochlorothiazide). Caution is required for patients with Severe Renal Impairment (creatinine clearance less than 30 mL/min).


Time- or Duration-Related Safety Patterns are also noted. Symptomatic Hypotension is more likely to occur upon Treatment Initiation. Additionally, long-term exposure to Hydrochlorothiazide is associated with an increased risk of Non-Melanoma Skin Cancer, a consideration based on cumulative dose.

Advertisements

Overdose and Emergency Response

Overdose with Vocado HCT is officially documented to present primarily as profound and prolonged systemic hypotension due to the combined action of Amlodipine and Olmesartan Medoxomil. This critical drop in blood pressure may lead to shock or the worsening of existing cardiac conditions, potentially manifesting as myocardial infarction or increased angina. Additionally, overdose can lead to severe fluid and electrolyte disturbances, such as hypokalemia and hyponatremia, related to the Hydrochlorothiazide component.

Regulators mandate that individuals must seek immediate medical attention for any signs of severe hypotension, fainting, or symptoms suggestive of a heart event, and should contact a certified regional Poison Control Center for specialized guidance. In an overdose situation, the official documentation describes placing the patient in a supine position and, if necessary, administering an intravenous infusion of normal saline to address volume depletion. Management is strictly symptomatic and supportive, as no specific antidote is known. Because the Amlodipine component is highly protein bound, hemodialysis is not expected to be beneficial for drug removal. Close medical supervision and monitoring of serum electrolytes are required following exposure.

Advertisements

Therapeutic Uses of Vocado HCT

What Vocado HCT Treats: Main Uses and Benefits

Vocado HCT is commonly used for the long-term management of essential hypertension (high blood pressure). It is a relevant medication option considered for patients whose condition shows resistance to conventional therapy, meaning their blood pressure remains elevated despite treatment with two different antihypertensive agents. The medicine is applied to provide additional blood pressure lowering when necessary, rather than as an initial treatment.

Therapeutic Applications and Benefits

The core therapeutic domains include treating uncontrolled essential hypertension, providing a consistent reduction in arterial pressure, and managing the associated long-term risk of major cardiovascular events like stroke, heart attack, and heart failure. This triple-combination approach helps in the process of achieving the required target pressure goals when simpler options have been insufficient.

“The fixed-dose combination generally provides the benefit of consistent blood pressure lowering, as it is applied across domains where additional symptomatic support is needed.”

Quick Fact: Relief for Systemic Imbalance
This medicine is commonly used when symptoms related to systemic imbalance (high pressure) create noticeable physiological strain, assisting with maintaining functional stability over the long term.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Vocado HCT?

Eligibility for Vocado HCT is strictly determined by regulatory labeling, outlining specific populations who are permitted or prohibited from using the medicine.

Populations with Absolute Contraindications

The medicine is absolutely contraindicated (must not be used) in several groups, as the risks outweigh potential benefits according to official labeling. These include individuals with known hypersensitivity to Olmesartan, Amlodipine, Hydrochlorothiazide, or any sulfonamide-derived drug. Use is prohibited in patients with severe renal impairment (creatinine clearance le 30 mL/min), anuria, severe hepatic impairment, or biliary obstruction.

Contraindicated Status Specific Condition or Population
Prohibited Use Pregnancy (especially second and third trimesters)
Prohibited Use Patients with Diabetes Mellitus also taking aliskiren
Prohibited Use Cardiogenic shock or severe aortic stenosis

Eligibility Based on Age and Condition

Vocado HCT is approved for use only in adults (18 years and older). Use in the pediatric population (below 18 years) is not recommended because safety and effectiveness have not been established by regulatory authorities. Patients with mild to moderate renal or hepatic impairment may use the medicine, but require careful monitoring and potential dosage restrictions. Furthermore, a volume- or salt-depleted state must be corrected prior to starting this medication.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vocado HCT, a fixed-dose combination of Amlodipine, Olmesartan Medoxomil, and Hydrochlorothiazide, has documented interaction patterns arising from each of its three components, as defined in official regulatory documents.

Interaction Restrictions and Contraindications

Co-administration with Aliskiren is contraindicated for patients with diabetes mellitus or moderate to severe renal impairment. The combination with Lithium is generally advised against due to the risk of toxicity resulting from reduced renal clearance by the diuretic component. Dual blockade of the Renin-Angiotensin System (RAS) using ACE-inhibitors or other ARBs alongside Vocado HCT is generally not recommended.

Pharmacokinetic and Exposure Constraints

The Amlodipine component may inhibit the metabolism of certain co-administered drugs. For instance, the dose of Simvastatin must be officially limited to 20 mg daily due to increased systemic exposure. The combination with moderate or strong CYP3A inhibitors may also increase Amlodipine exposure. Conversely, agents such as Cholestyramine and Colestipol resins interfere with absorption and require mandatory dose separation, often 4 hours before or 4–6 hours after the resins.

Pharmacodynamic Effects

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the effectiveness of the antihypertensive and diuretic effects. Additive effects on blood pressure lowering may occur with Alcohol or Narcotics, leading to potentiated orthostatic hypotension. Corticosteroids may intensify the risk of hypokalemia.

Advertisements

Mechanism of Action

Vocado HCT modulates cardiovascular dynamics through two distinct, complementary pathways involving its components, Olmesartan and Hydrochlorothiazide.

AT1 Receptor Blockade and Signaling

Olmesartan, an Angiotensin II Receptor Blocker (ARB), acts by selectively binding to the Angiotensin II type 1 ( AT1) receptors located on vascular smooth muscle and various other tissues. This interaction prevents the binding of Angiotensin II, thereby suppressing the effects of the renin-angiotensin system (RAS). The resulting mechanistic cascade includes the reduction of peripheral arteriolar tone, the inhibition of aldosterone synthesis and release, and the subsequent reduction of vasoconstrictive signaling.


Renal Sodium-Chloride Cotransporter Inhibition

The second component, Hydrochlorothiazide (HCTZ), functions by inhibiting the sodium-chloride ( Na^+/ Cl^-) cotransporter (NCC) situated in the apical membrane of the distal convoluted tubule cells in the kidney. This molecular action decreases the reabsorption of sodium and chloride ions from the tubular lumen. The increased delivery of Na^+ and water to the collecting ducts stimulates increased urinary excretion of water and ions, leading to a subsequent reduction of total circulating plasma volume.

Advertisements

Dosage and Administration Information

Vocado HCT is administered solely via the oral route as a fixed-dose film-coated tablet. The required procedural step is to swallow the tablet whole with water; the tablet must not be broken, crushed, or chewed to maintain the integrity of the three-component dose.

Standard Regimen and Timing

The medication is designated for a once-daily (q.d.) dosing schedule. Patients are instructed to take the tablet at the same time each day, preferably in the morning, to ensure consistent blood pressure control. The dose may be taken with or without food. The maximum recommended daily dose is one tablet of the 40 mg Olmesartan / 10 mg Amlodipine / 25 mg Hydrochlorothiazide strength.

Usage Patterns and Constraints

Vocado HCT is generally utilized as add-on therapy for individuals whose blood pressure remains uncontrolled on a dual combination, or as substitution therapy for patients already stabilized on the three separate components. Dosage adjustments, if required, should be reviewed and made no more frequently than two weeks after the previous change. The medication is not recommended for use in the pediatric population (under 18 years) or in patients with severe renal or severe hepatic impairment. If a dose is missed, it should be taken immediately unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped; patients must not take a double dose to compensate for the omission.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vocado HCT

Evidence for Use in Uncontrolled High Blood Pressure

Research on this medicine was primarily conducted through short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving adults whose blood pressure was not adequately controlled after being treated with a combination of two other antihypertensive medicines. Researchers examined whether the combination was associated with changes in blood pressure. The main outcomes measured were changes in the top number (Systolic BP) and the bottom number (Diastolic BP) when measured while seated, as well as the proportion of patients who achieved specific blood pressure target goals.

Studies reported measurements of seated SBP and DBP reductions from the starting point in the specific patient groups observed. Research highlights changes measured during the study period, documenting patterns related to the blood pressure measurements observed. These findings contribute to understanding symptom patterns and help contextualize how patients reported their experience during the trials.


Evidence on Long-Term Management and Cardiovascular Outcomes

This fixed-dose combination was observed in studies exploring long-term outcomes for chronic hypertension. While the core studies on the fixed-dose product focused on short-term blood pressure changes, evidence for long-term outcomes, such as the incidence of major cardiovascular events (like stroke or heart attack), is drawn from extensive, long-running research on the three separate component drug classes (the ARB, the CCB, and the diuretic).

Research describes that the component drug classes' role in research exploring observed blood pressure reductions was explored in trials. Research into the component drug classes described patterns of lower incidence of major cardiovascular events in patients with observed blood pressure reductions over many years. The long-term data is therefore extrapolated from the research on the component medications to examine data related to long-term outcomes.


Studies in Specific Populations

Research examined this combination in specific groups within the general hypertensive population. Studies explored different populations based on age, including older adults (over 65 years old), and whether the medicine was evaluated in those with varying levels of hypertension severity. Research findings for blood pressure measurements were described across the subgroups of patients studied. However, follow-up durations were limited in the primary comparative trials. Data for certain groups, such as those with severe kidney issues or women who are pregnant, remain insufficient or not fully established in the primary research for this specific combination.


Research Gaps and Remaining Uncertainty

A key limitation is that dedicated, multi-year randomized clinical trials of the fixed triple-combination product specifically designed to directly measure a reduction in major outcomes like stroke or myocardial infarction have not been performed. Furthermore, comparative evidence that directly evaluates this triple combination against other three-drug regimens is lacking. Research provides insight into short-term changes, but there is limited information available regarding long-term outcomes and the sustainability of blood pressure measurements over time.

Key Studies & References

  1. Hypertension in adults: diagnosis and management (NICE Guideline NG136)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Vocado HCT (FAQ)


Q: How is Vocado HCT different from other 'Vocado' medicines?

A: Vocado HCT is classified in regulatory documents as a triple-combination product. This means it combines three distinct active ingredients—Amlodipine, Olmesartan, and Hydrochlorothiazide—into a single tablet. Other products sold under the 'Vocado' name typically contain only one or two of these three components.


Q: Why does Vocado HCT contain two different ingredients?

A: According to official product information, this medicine actually contains three active ingredients that belong to three separate classes of medicine. These components—Olmesartan, Amlodipine, and Hydrochlorothiazide—work through complementary physiological mechanisms to achieve blood pressure reduction.


Q: Can Vocado HCT cause changes in kidney function?

A: Yes, official documents state that this medicine is not recommended for individuals with severe kidney impairment. For other patients, regulatory information advises that changes in kidney function should be monitored regularly by a healthcare provider while taking this medication.


Q: What should I know about taking Vocado HCT if I have diabetes?

A: Official prescribing information includes a strict contraindication for patients with diabetes mellitus if they are also taking a medicine called aliskiren. This is an absolute prohibition on co-administration for this specific group.


Q: What types of supplements should be avoided while taking Vocado HCT?

A: Because one component, the diuretic, can affect electrolyte balance, caution is described regarding the use of supplements or salt substitutes that contain potassium. Official guidance emphasizes discussing all supplements, including herbal products, with a healthcare provider due to potential interactions.


Q: Is Vocado HCT safe for older adults (seniors)?

A: Clinical studies for this medication have included older patients (65 years and older). While general dosage adjustments for this group are not universally specified, the regulatory information emphasizes that the use of the medicine requires careful observation and monitoring in elderly patients.


Q: Is there recent evidence about Vocado HCT and heart health?

A: Direct long-term studies designed to measure major outcomes like heart attack or stroke for the specific fixed triple-combination are limited. Research exploring these cardiovascular outcomes is instead extrapolated from extensive studies conducted on the three component drug classes individually.


Q: What is the difference between Vocado HCT and a plain diuretic?

A: A plain diuretic works only by helping the kidneys excete excess salt and water, primarily for fluid regulation. Vocado HCT contains a diuretic plus two other active components (an ARB and a CCB) that also act directly to relax blood vessels and prevent hormonal vessel constriction.


Q: What is the recommended approach if someone feels dizzy after starting Vocado HCT?

A: Dizziness is listed in regulatory documents as a commonly reported side effect, particularly when treatment begins, due to the possibility of symptomatic hypotension (low blood pressure). While this possibility is described in the official warnings, regulatory information does not provide personal, patient-directed action plans.


Q: Can Vocado HCT cause joint pain or gout attacks?

A: The Hydrochlorothiazide component is described in regulatory documents as sometimes causing a temporary increase in blood uric acid levels. Elevated uric acid is associated with the development of conditions like gout. Joint pain itself is not typically listed as a common effect.


Q: Are there specific food restrictions while taking Vocado HCT?

A: No specific general food restrictions are listed, and the medicine can be taken with or without food. However, regulatory documents mention that the diuretic component may require consideration of dietary sodium or salt intake.


Q: What is the official dosage range described in regulatory documents for Vocado HCT?

A: According to the FDA and similar agencies, the medicine is officially available in a range of fixed-dose combinations. These strengths are documented to exist up to a maximum dose of 40 mg / 10 mg / 25 mg (Olmesartan/Amlodipine/HCTZ).


Q: How is the safety profile of Vocado HCT described for patients with heart failure?

A: The medicine is contraindicated (prohibited) for patients who are experiencing cardiogenic shock. For patients with heart failure who are not in shock, regulatory documents state that caution is advised during use, particularly due to the presence of the Amlodipine component.


Q: What should be monitored by a healthcare provider while a patient is taking Vocado HCT?

A: Regulatory documents advise that a healthcare provider should monitor several key parameters during treatment. These typically include blood pressure control, changes in kidney function, and the balance of serum electrolytes (substances like potassium) in the blood.


Q: How long does it typically take to see results with Vocado HCT?

A: According to pharmacodynamic studies described in official labeling, the maximum blood pressure lowering effect is typically described as being achieved within two weeks after the patient is stabilized on a specific dose strength.


Q: Is it common to have muscle cramps while taking Vocado HCT?

A: Muscle cramps or spasms are listed in official regulatory documents as an uncommon adverse reaction. This means they occur infrequently, usually in less than 1 out of every 100 people observed in clinical studies.


Q: Is there a risk of developing a cough with Vocado HCT?

A: A cough is listed in official documentation as an uncommon side effect associated with the medicine. This reaction is generally observed infrequently across patient populations.


Q: Does grapefruit juice interact with Vocado HCT?

A: Yes, regulatory information notes that consuming grapefruit or grapefruit juice may increase the amount of the Amlodipine component in the bloodstream. Official guidance recommends against co-consumption to prevent a potential increase in exposure to the drug.


Q: Are there any limitations on who can use Vocado HCT based on race or ethnicity?

A: Official clinical study documents sometimes describe differences in drug response based on patient population. It is noted that the Olmesartan component may be less effective in lowering blood pressure in African American patients compared to non-Black patients.


Q: Does Vocado HCT have a Black Box Warning?

A: Yes, official FDA labeling includes a Boxed Warning (often called a 'Black Box Warning') required for drugs that act on the renin-angiotensin system. This specific warning concerns the risk to the developing fetus if the drug is used during the second and third trimesters of pregnancy.


Q: Does Vocado HCT require routine blood tests?

A: Official documents state that blood tests are recommended to monitor the patient's condition. These typically include checking serum electrolytes and renal function (kidney tests) regularly throughout the course of treatment.


Q: Is there a generic version of Vocado HCT available?

A: Official regulatory databases in various countries that track approved medications indicate the availability status of generic versions for this fixed-dose combination product. The availability of generics may vary by specific strength and region.


Q: Can Vocado HCT cause sensitivity to the sun?

A: Sensitivity to light, known as photosensitivity, is listed as an uncommon adverse reaction in official regulatory documentation. This effect is often linked to the Hydrochlorothiazide component of the medication.


Q: Does stopping Vocado HCT suddenly cause any issues?

A: Regulatory documentation describes that abrupt discontinuation of the medicine is generally not advised. Stopping the treatment suddenly may be associated with a rebound increase in blood pressure measurements.


Q: Is the effectiveness of Vocado HCT changed by taking antacids?

A: Regulatory texts contain warnings about co-administering the drug with absorption-altering substances, such as certain resins. This indicates that some substances may interfere with the medicine's absorption and therefore change its effectiveness.


Q: Can Vocado HCT affect cholesterol levels?

A: The Hydrochlorothiazide component is described in regulatory documents as sometimes causing temporary changes to serum lipid levels, which includes cholesterol. This is a factor that would typically be monitored by a healthcare provider.

Advertisements

How should Vocado HCT be stored and disposed of?

How to Store and Dispose of Vocado HCT?

Vocado HCT tablets must be stored at Controlled Room Temperature, which is generally maintained between 20 C and 25 C (68 F to 77 F), with excursions up to 30 C permitted. The medication must be kept from freezing and protected from moisture, heat, and direct light. Always store the tablets in their closed container until the time of use to maintain product stability and potency.

Packaging and Safety

Requirement Status
Temperature Controlled Room Temp. (20 C–25 C)
Protection Avoid freezing, moisture, and light
Child Safety Must be kept out of reach of children
Expiration Do not take after the expiry date

Disposal

Disposal of unused or expired Vocado HCT should be done through a drug take-back location or a pharmacy take-back program. This medicine is not on the list for disposal by flushing down the toilet. If a take-back program is unavailable, dispose of the tablets in household trash by first mixing them with an unappealing substance like dirt or used coffee grounds.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vocado HCT found in:

A-Z Index: